# PT-141 for Men: Off-Label and Investigational Erectile Research > PT-141 for Men: Off-Label and Investigational Erectile Research. The 2004 intranasal and subcutaneous studies, the central mechanism, and the 2024 Phase 2 PDE-5 combination — none of it FDA-approved for men. Bremelanotide is not approved for men. There is real early-phase erectile-response data and a 2024 Phase 2 pipeline — and it is all investigational. Here is exactly what that research found, and what it does not establish. ## In plain English PT-141 for men is **off-label** — not an approved use. That said, the male story is where this compound started. In the early 2000s, researchers tested it in men with erection problems, first as a nasal spray and then as an injection, and saw dose-dependent erectile responses. Because it works on the brain's desire circuitry rather than on blood flow, it is being studied **alongside** the standard blood-flow drugs (not as a replacement) for men those drugs do not help. None of this is FDA-approved for men, and the evidence is early-phase. This page lays out what the male research actually found, and stops where the data stops. ## Is PT-141 approved for men? No. Bremelanotide's FDA approval covers **only** premenopausal women with HSDD [6]. There is early-phase erectile-response data in men, but male use remains off-label and investigational, and no male indication has been approved [6][1]. Every claim on this page should be read against that fact: this is research, not a sanctioned treatment for men. Material sold as "PT-141 research chemical" for male use is laboratory material outside the pharmaceutical framework, with no oversight of identity, purity, or concentration [11]. ## What does PT-141 do for men? The early-phase erectile data In early-phase research, PT-141 produced **rapid, dose-dependent erectile activity** in men with erectile dysfunction, via a central mechanism [1]. The foundational pharmacology (Molinoff 2003) showed that systemic administration produced erections in animals and men and activated hypothalamic neurons — the same central, brain-level mechanism that defines the compound [1]. This is a different route to the same endpoint than the established therapy: rather than improving penile blood flow peripherally, PT-141 acts on the brain circuits of sexual response [1]. That mechanistic difference is the entire rationale for the combination work below — and it is also why the male data should not be read as a finished, approved result. It is an investigational signal [9]. ## Does PT-141 nasal spray work? The **intranasal** formulation was the original delivery route in men's-ED research. In healthy men and PDE-5-inhibitor-responsive ED patients, intranasal PT-141 produced dose-dependent Cmax and AUC, a median Tmax of 0.50 hours, and a terminal half-life of 1.85-2.09 hours [7]. A statistically significant erectile response versus placebo appeared at doses **above 7 mg**, with onset of first erection around 30 minutes [7]. So: it produced a measurable effect — and the intranasal program was later discontinued for pharmacokinetic variability, with development moving to subcutaneous injection [7][8]. The nasal-spray data is a real early result and a closed chapter of the formulation history, not an endorsement of any current nasal product. ## The subcutaneous transition and the salvage-study caveat A subsequent study evaluated **subcutaneously** administered PT-141 in healthy men and in patients with an inadequate response to sildenafil, characterizing its safety, pharmacokinetics, and erectile pharmacodynamics — the work that informed the move to the subcutaneous route [8]. One honesty note for anyone reading the older male literature: a 2008 Safarinejad & Hosseini erectile-dysfunction salvage study received a 2023 **Expression of Concern** (a formal editorial notice that a study's integrity is in question), and its findings should be treated as disputed [11]. A review of novel emerging ED therapies places melanocortin receptor agonists such as bremelanotide among investigational, centrally acting approaches — useful class context, not evidence of approval [9]. ## Why is PT-141 being studied with a PDE-5 inhibitor? Because the two mechanisms are **complementary**: PT-141 acts centrally on desire, while PDE-5 inhibitors act peripherally on blood flow [1]. The development logic is not replacement but combination — for men a blood-flow drug alone does not help. In June 2024 the developer announced initiation of a **Phase 2 study** (~50 patients) of bremelanotide co-administered with a PDE-5 inhibitor for erectile dysfunction in patients who do not respond to PDE-5-inhibitor monotherapy, with a co-formulation IND and a potential Phase 3 planned [14]. This is a corporate press release describing a pipeline step — it is a development-status statement, not a clinical result, and it does not change the approval status for men [14]. For a clinic-context data point, a 2024 sexual-medicine conference abstract described real-world off-label use of the CNS agent bremelanotide in men — lower-tier evidence, included for completeness [13]. Remote evaluation workflows for sexual-medicine patients have also been reviewed in the context of access to these therapies [10]. --- The PT-141 (bremelanotide) record folded into clean planes — the one approved use creased apart from the off-label male research, the modest effect set beside the number that qualifies it, and the nausea-led tolerability cost read in plain sight, with the unverified field reports tucked behind a dashed fold; no clinic behind the paper and nothing here dosed, dispensed, or sold.